

EXERCISE OF WARRANTS OF SERIES TO 1

Exercise period 12-26 September 2024

IMPORTANT INFORMATION

This information document has been prepared by Diagonal Bio AB ("Diagonal Bio" or the "Company"). The reader is asked to read the prospectus published by Diagonal Bio on 3 April 2024, in connection with the Company's rights issue, for a description of the risks associated with an investment in the Company. The prospectus is available for download on the Company's website (www.diagonalbio.com).

DIAGONAL BIO AB

Diagonal Bio is a Swedish biotechnology company with the vision to limit the global spread of infectious diseases. Through a patented platform technology, Diagonal Bio develops easy-to-use and cost-effective analytical instruments to quickly and accurately identify genetic markers (DNA or RNA) from, for example, viruses, bacteria and fungi. This is important in several market segments, such as agriculture, livestock, fish farming, companion animals, food, water and other beverages, and in research for pathogen identification.

The Company's technology offers the same accuracy as today's leading analytical method - PCR - but without the dependence on complex logistics or large central laboratories, as the Company's tests can be performed on site. The technology enables analysis of current and future infectious diseases within 10-15 minutes of sample collection.

Diagonal Bio is developing two separate product lines for different market segments:

- LAMPlify® for the less regulated market segments (e.g. agriculture, pets, food and beverages) where the CE marking according to the Low Voltage Directive (LVD) is sufficient. LAMPlify® is suitable for use in both veterinary clinics and laboratory settings, where PCR-based methods have traditionally been used to identify genetic markers.
- PANVIRAL® for in vitro diagnostics for e.g. hospitals, health centers and laboratories (e.g. accredited human diagnostic laboratories).

In April 2024, the Company carried out a rights issue of units, which provided the Company with approximately SEK 18 million before deduction of issuing costs. Through the rights issue, in addition to shares, warrants of series TO 1 were issued. The funds that the Company may receive through the exercise of TO 1 (after deduction of issue costs) are intended to finance the continued commercialisation of LAMPlify®.

SUMMARY OF THE OFFER

Exercise period:	12-26 September 2024.
Exercise price:	SEK 0,05 per share.
Last day of trading in TO 1:	24 September 2024.
Number of outstanding shares prior to warrant exercise:	400.636.419 shares.
Issue volume:	If warrants of series TO 1 are fully exercised, approximately SEK 2,25 million will be added to the Company before issue costs.
ISIN-code for TO 1:	SE0021921517.

TERMS IN SHORT

There are 45.082.580 issued warrants of series TO 1. Holders of warrants of series TO 1 have the right to subscribe for one (1) new share in Diagonal Bio at a price of SEK 0,05 per share for each warrant. Subscription with the support of warrants of series TO 1 can take place during the period from and including 12 September 2024 to and including 26 September 2024. Subscription must take place by simultaneous cash payment no later than 17:00 CET on 26 September 2024.

You need to take a position on the offer as a warrant holder - this is how you exercise your warrants of series TO 1

In order for your warrants not to expire worthless, you are required to subscribe for new shares, supported by warrants, by 17:00 CET on 26 September 2024 at the latest, or sell your warrants by 24 September 2024 at the latest.

You can have your warrants registered in two ways:

1. In a securities depository in a bank or with another administrator (for example Avanza or Nordnet), in an investment savings account (ISK) or in a capital insurance (KF). Your warrants are then trustee-registered.
2. On a VP account (a VP account starts with three zeros). Your warrants are then direct-registered.

If your warrants are trustee-registered

Subscription and payment of new shares, with the support of warrants, must be made to the respective bank or other administrator where the warrants are registered. Subscription and payment shall be made in accordance with the instructions provided by each such bank or trustee. Usually the bank/custodian sends out a digital notice to the account holder, otherwise it is usually sufficient to log in to the securities depository from the first day of the exercise period to receive instructions on how to use warrants to subscribe for new shares. Please contact your bank or trustee if you cannot find these instructions. Note that banks and other administrators may set different time limits for subscription, therefore it is recommended that you contact your bank/administrator early in the usage period to obtain information about subscription and payment. Subscribed and paid shares may be registered in your securities depository as "interim shares"

NOTE - In order for your warrants not to expire worthless, it is required that you actively subscribe and pay for shares no later than 17:00 CET on 26 September 2024, or sell your warrants no later than 24 September 2024.

For any questions regarding warrants of series TO 1, please contact Sedermera or Nordic Issuing. Sedermera and Nordic Issuing act as financial advisor and issuing agent respectively for Diagonal Bio in connection with warrant exercise. Markets & Corporate Law Nordic AB acts as legal adviser.

Sedermera Corporate Finance AB

Phone: +46 (0)40-615 14 10
E-mail: cf@sedermera.se

Nordic Issuing AB

Phone: +46 (0)40-632 00 20
E-mail: info@nordic-issuing.se

or "IA" until registration of the issue is completed with the Swedish Companies Registration Office, whereupon interim shares are automatically exchanged for ordinary shares in Diagonal Bio.

If your warrants are direct-registered

No issue statement will be sent out. Subscription of new shares with the support of warrants must be done by sending in a completely completed subscription form to Nordic Issuing AB ("Nordic Issuing") via e-mail. In connection with the subscription form being sent to Nordic Issuing, payment must be made according to the payment instructions on the subscription form. The registration form and this folder are kept available on the Company's website (www.diagonalbio.com), Sedermera Corporate Finance AB's ("Sedermera") website (www.sedermera.se) and Nordic Issuing's website (www.nordic-issuing.se).

Completed subscription form and payment must reach Nordic Issuing no later than 17:00 CET on 26 September 2024. Subscribed and paid shares will be registered in your VP account as "interim shares" or "IA" until registration of the issue is completed with The Swedish Companies Registration Office, whereupon interim shares are automatically exchanged for ordinary shares in Diagonal Bio.

Subscription over EUR 15,000 where applicable

In the event that your subscription amounts to or exceeds EUR 15.000, a money laundering form must be completed and submitted to Nordic Issuing in accordance with the Act (2017:630) on measures against money laundering and financing of terrorism, at the same time as payment is made. Please note that interim shares cannot be booked, even though payment has been received, until the money laundering control is available to Nordic Issuing. Money laundering forms are obtained from Nordic Issuing.

Important dates for warrants of series TO 1

- 12 September 2024 - Exercise period starts
- 24 September 2024 - Last day for trading in warrants
- 26 September 2024 - Exercise period ends
- 27 September 2024 - Planned date for announcement of outcome of the warrant exercise
- 11 October 2024 - Planned date for change from interim shares to ordinary shares